The 56th annual meeting of the American Society of Hematology (ASH) featured a number of important studies in multiple myeloma, including trials of carfilzomib, pomalidomide,ixazomib, and two new antibodies.
Dimopoulos MA, Palumbo A, Weisel K, et al. Safety and efficacy in the Stratus (MM-010) trial, a single-arm phase 3b study evaluating pomalidomide + low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma. Program and abstracts of the 56th ASH Annual Meeting and Exposition, December 6-9, 2014; San Francisco, California. Abstract 80.
Kumar S, Berdeja JG, Niesvizky R, et al. Long-term ixazomib maintenance is tolerable and improves depth of response following ixazomib-lenalidomide-dexamethasone induction in patients (Pts) with previously untreated multiple myeloma (MM): phase 2 study results. Program and abstracts of the 56th ASH Annual Meeting and Exposition, December 6-9, 2014; San Francisco, California. Abstract 82.
Martin III TG, Baz R, Benson Jr. DM, et al. A phase Ib dose escalation trial of SAR650984 (anti-CD-38 mAb) in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma. Program and abstracts of the 56th ASH Annual Meeting and Exposition, December 6-9, 2014; San Francisco, California. Abstract 83.
Plesner T, Arkenau HT, Lokhorst HM, et al. Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Program and abstracts of the 56th ASH Annual Meeting and Exposition, December 6-9, 2014; San Francisco, California. Abstract 84.
More 56th ASH Annual Meeting Abstracts are here.
No comments:
Post a Comment